Moderna’s COVID-19 Vaccine Shows Promise in Early Trial Results

Moderna reported positive early results from a phase 1 trial of its COVID-19 vaccine candidate, mRNA-1273, with all participants producing antibodies to the virus within 15 days of a single dose.

Patients who received two doses at 100 mcg had levels of antibodies that exceeded those seen in convalescent plasma from recovered patients.   

Participants given the lower dose of 25 mcg had levels of antibodies equivalent to those seen in convalescent plasma from COVID-19 survivors.